[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"toripalimab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:toripalimab":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,79,104,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100648929","phase-1-neoadjuvant-propranolol-plus-sox-and-toripalimab-for-locally-advanced-gastricgej-adenocarcinoma-100648929",false,"NCT07727993","Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric\u002FGEJ Adenocarcinoma","A Prospective, Open-Label, Single-Arm, Phase Ib\u002FII Study of Neoadjuvant Propranolol Plus SOX Chemotherapy and Toripalimab in Patients With Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Voluntary participation in the study, with written informed consent, and willingness and ability to comply with the study treatment and follow-up requirements.\n2. Male or female participants aged 18 to 75 years.\n3. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma.Resectable locally advanced disease as determined by imaging assessment or a multidisciplinary team according to the eighth edition of the American Joint Committee on Cancer staging system, generally defined as cT3-4a with any N category, or any T category with node-positive disease, corresponding to stage II-III disease, without distant metastasis.\n4. Eastern Cooperative Oncology Group performance status of 0 or 1.\n5. Acceptable cardiopulmonary function, including all of the following:\n\n(1)No clinically significant abnormality on electrocardiography; (2)Resting heart rate of at least 60 beats per minute; (3)Systolic blood pressure of at least 90 mmHg; (4)No progressive or decompensated cardiopulmonary disease; (5)Left ventricular ejection fraction of at least 50%. 6.Adequate organ function during screening, defined as follows:\n\n1. Absolute neutrophil count of at least 1.5 × 10⁹\u002FL;\n2. Platelet count of at least 75 × 10⁹\u002FL;\n3. Hemoglobin level of at least 90 g\u002FL;\n4. Total bilirubin no greater than 1.5 times the upper limit of normal;\n5. Aspartate aminotransferase and alanine aminotransferase no greater than 2.5 times the upper limit of normal;\n6. Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 50 mL\u002Fmin;\n7. International normalized ratio no greater than 1.5 times the upper limit of normal, unless the participant is receiving stable anticoagulation and is considered eligible by the investigator.\n\n7.Female participants of childbearing potential must have a negative pregnancy test during screening. Male and female participants of reproductive potential must agree to use effective contraception during the study and for at least 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n1. Distant metastatic disease confirmed by imaging or diagnostic laparoscopy, including but not limited to peritoneal, hepatic, or bone metastases, or positive peritoneal cytology.\n2. Previous systemic anticancer treatment for the current malignancy, including chemotherapy, immunotherapy, or targeted therapy, or previous radiotherapy. Diagnostic endoscopy and biopsy are permitted.\n3. Grade 2 or higher peripheral neuropathy at baseline.\n4. A second primary malignancy requiring systemic treatment within the previous 3 years, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, low-risk thyroid cancer, or other malignancies considered cured.\n5. Inability to tolerate curative-intent surgery or study treatment, as determined by the investigator.\n6. Active autoimmune disease, or a clinically significant history of autoimmune disease requiring systemic immunosuppressive treatment within the previous 2 years. Participants with type 1 diabetes mellitus, stable thyroid disease requiring replacement therapy, vitiligo, or grade 2 or lower psoriasis not requiring systemic treatment may be eligible.\n7. Use of systemic corticosteroids at a prednisone-equivalent dose of at least 10 mg\u002Fday, or other systemic immunosuppressive agents, within 14 days before the planned initiation of immunotherapy. Physiologic replacement therapy, inhaled or topical corticosteroids, and short-term prophylactic treatment related to surgery are permitted.\n8. Active infection, including but not limited to active tuberculosis, uncontrolled hepatitis B virus or hepatitis C virus infection, human immunodeficiency virus infection, or another serious infection requiring intravenous antibiotic treatment.\n9. Any contraindication to propranolol, including:\n\n(1)Bronchial asthma or a risk of bronchospasm; (2)Diabetic ketoacidosis or metabolic acidosis; (3)Severe or symptomatic bradycardia; (4)Second- or third-degree atrioventricular block, sinoatrial block, or sick sinus syndrome; (5)Cardiogenic shock; (6)Right-sided heart failure caused by pulmonary hypertension; (7)Congestive heart failure; (8)Clinically significant hypotension; (9)Prolonged fasting; (10)Severe peripheral circulatory failure; (11)Untreated pheochromocytoma; (12)Variant angina; (13)Concomitant treatment with rizatriptan benzoate. 10.Moderate or severe chronic obstructive pulmonary disease with a recent acute exacerbation.\n\n11.Active upper gastrointestinal bleeding at baseline, melena or hematemesis within the previous 4 weeks, bleeding requiring blood transfusion or endoscopic hemostasis, uncontrolled peptic ulcer disease, or a high risk of recent bleeding as determined by the investigator.\n\n12.Requirement for continuous full-dose anticoagulation, dual antiplatelet therapy that cannot be interrupted, or a bleeding disorder that cannot be adequately managed during the perioperative period.\n\n13.Known hypersensitivity to propranolol, oxaliplatin, S-1 or fluoropyrimidines, toripalimab, or any of their excipients, or a history of a severe adverse reaction to any of these agents.\n\n14.Concomitant use of medications that cannot be discontinued or replaced and that may cause clinically significant interactions with propranolol, including verapamil, diltiazem, class I or class III antiarrhythmic agents, strong CYP2D6 or CYP1A2 inhibitors, or other medications considered by the investigator to pose a major drug-drug interaction risk.\n\n15.Uncontrolled bleeding disorder, or major surgery or serious trauma within 4 weeks before enrollment, excluding the curative-intent surgery planned as part of this study.\n\n16.Pregnancy or breastfeeding, or unwillingness to use the required contraceptive measures.\n\n17.Any medical, psychiatric, social, or other condition that, in the investigator's judgment, may compromise participant safety, treatment compliance, or completion of the required follow-up, including severe psychiatric illness, substance abuse, or inability to attend scheduled visits.","ALL","18 Years","75 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a single-center, prospective, open-label, single-arm, phase Ib\u002FII study evaluating the safety and efficacy of neoadjuvant propranolol combined with SOX chemotherapy and toripalimab in patients with resectable locally advanced gastric or gastroesophageal junction adenocarcinoma. A total of 49 participants will be enrolled. Stage 1 includes an initial safety lead-in of 12 participants, followed by efficacy evaluation using a Simon two-stage design. Participants will receive propranolol, toripalimab, oxaliplatin, and S-1 during the neoadjuvant period, followed by curative-intent surgery.\n\nThe primary efficacy endpoint is pathological complete response. Secondary endpoints include safety and tolerability, major pathological response, R0 resection rate, event-free survival, recurrence-free survival, and overall survival. Exploratory analyses will assess changes in adrenergic stress markers, heart rate variability, peripheral immune parameters, β-adrenergic receptor signaling, and the tumor immune microenvironment.",[28,29,30,31],"Gastric or Gastroesophageal Junction Adenocarcinoma","Propranolol","SOX Chemotherapy","Toripalimab",[33,34,35,36,37],"gastric or gastroesophageal junction adenocarcinoma","propranolol","OX chemotherapy","toripalimab","neoadjuvant therapy","NOT_YET_RECRUITING","2026-07-22",{"date":41,"type":42},"2026-07-27","ACTUAL",{"date":44,"type":21},"2026-08-01",{"date":46,"type":21},"2027-12-31",{"name":48,"class":49},"Ting Liu","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100571395","phase-2-concurrent-chemoradiotherapy-combined-with-toripalimab-and-surufatinib-in-the-treatment-of-limited-stage-small-cell-lung-cancer-100571395","NCT06719700","Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","A Prospective Phase II Study of Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Informed Consent: An informed consent form, signed and dated, must be provided before any steps in the study are performed.\n* Age: Males or females aged 18 to 75 years.\n* Diagnosis: Histologically or cytologically confirmed small cell lung cancer (SCLC).\n* Stage: Stage I-III (AJCC\u002FUICC 8th edition TNM staging), where all lesions can be included in a single radical radiotherapy plan (i.e., limited-stage disease). Stage I-II must be inoperable.\n* Life Expectancy: ≥12 weeks.\n* Performance Status (PS): WHO PS score of 0 or 1.\n* Postmenopausal women or those with a negative urine or serum pregnancy test (HCG sensitivity ≥25 IU\u002FL or equivalent) within 7 days before starting study treatment.\n* Female participants must not be breastfeeding.\n* Women of childbearing potential (WOCBP) must agree to use contraception during study treatment and for 3 months after the last dose of study drug (i.e., 30 days for an ovulation cycle plus approximately 5 half-lives of the investigational drug).\n* Male participants engaging in sexual activity with WOCBP must agree to use contraception during study treatment and for 5 months after the last dose of study drug (i.e., 90 days for sperm regeneration cycle plus approximately 5 half-lives of the investigational drug).\n* Males with azoospermia do not need to follow contraception requirements.\n* WOCBP who are not sexually active do not need to follow contraception requirements but must still undergo pregnancy testing as outlined.\n* Organ and Bone Marrow Function:\n\nPulmonary Function: FEV1 ≥800 mL. Absolute neutrophil count ≥1.5 × 10⁹\u002FL. Platelet count ≥100 × 10⁹\u002FL. Hemoglobin ≥9.0 g\u002FdL. Renal Function: Calculated creatinine clearance ≥50 mL\u002Fmin using the Cockcroft-Gault formula.\n\nSerum bilirubin ≤1.5 × upper limit of normal (ULN). AST and ALT ≤2.5 × ULN.\n\nExclusion Criteria:\n\n* Participation in Another Clinical Trial: Simultaneous participation in another clinical trial, unless it is an observational (non-interventional) study.\n* Mixed Histology: Histological subtype of mixed small cell and non-small cell lung cancer (SCLC).\n* Extensive-Stage SCLC: Diagnosis of extensive-stage SCLC.\n* Malignant Effusions: Pathologically confirmed malignant pleural effusion or pericardial effusion.\n* Hemoptysis: Central cavitary SCLC with hemoptysis (hemoptysis volume \\>50 ml\u002Fday).\n* Immunosuppressive Treatment: Use of immunosuppressive drugs within 28 days prior to the first dose of toripalimab. Physiological doses of intranasal corticosteroids and systemic corticosteroids ≤10 mg daily of prednisone (or equivalent) are exceptions. Steroids used to manage chemoradiotherapy-related toxicities are allowed.\n* Previous Anti-PD-1\u002FPD-L1 Therapy: Prior use of any anti-PD-1 or anti-PD-L1 antibodies.\n* Major Surgery: Underwent major surgery (excluding vascular access) within 4 weeks before study entry.\n* Autoimmune Disease History: History of autoimmune diseases within the last 2 years, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis.\n* Primary Immunodeficiency: History of primary immunodeficiency.\n* Organ Transplant History: History of organ transplantation requiring immunosuppressive treatment.\n* QT Interval Prolongation: QTc interval (corrected by Bazett's formula) \\>470 ms, calculated from three ECG measurements.\n* Uncontrolled Comorbidities: Uncontrolled comorbid conditions, including but not limited to persistent or active infections, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, arrhythmias, active peptic ulcer disease or gastritis, active bleeding disorders, chronic hepatitis C, HIV infection, HBsAg-positive patients with DNA \\>500 IU\u002Fml, or any psychiatric or social conditions that may interfere with study requirements or the patient's ability to provide informed consent.\n* Tuberculosis History: Known history of tuberculosis.\n* Live Vaccination: Received a live attenuated vaccine within 30 days prior to study initiation.\n* Previous Primary Malignancy: History of another primary malignancy within 5 years prior to study entry, except for adequately treated basal or squamous cell carcinoma of the skin, in situ cervical cancer, ductal carcinoma in situ of the breast, or localized prostate cancer.\n* Pregnancy and Breastfeeding: Pregnant or breastfeeding women, or men and women of reproductive potential who are not using effective contraception.\n* Interference with Study Assessment: Any condition that may interfere with the evaluation of toripalimab's efficacy or safety.\n* Investigator's Discretion: Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.",{"count":58,"type":21},47,[25],"Based on the preclinical rationale for combining surufatinib with immunotherapy, and the clinical efficacy observed with surufatinib in extensive-stage small cell lung cancer (ES-SCLC), the investigators hypothesize that incorporating surufatinib into the ADRIATIC regimen could further enhance survival in LS-SCLC. To evaluate this approach, the investigators plan to conduct a single-arm Phase II study to explore the safety and efficacy of concurrent chemoradiotherapy combined with toripalimab and surufatinib in treating LS-SCLC.",[31,62,63,64],"Surufatinib","Chemoradiotherapy","Limited-stage Small Cell Lung Cancer (LS-SCLC)",[31,62,63,66,67],"Limited-stage small cell lung cancer (LS-SCLC)","Immunotherapy consolidation","RECRUITING","2026-02-28",{"date":71,"type":42},"2026-03-03",{"date":73,"type":42},"2024-11-30",{"date":75,"type":21},"2028-11-29",{"name":77,"class":49},"Sun Yat-sen University",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100616651","real-world-study-of-toripalimab-in-extensive-stage-small-cell-lung-cancer-100616651","NCT07308379","Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer","A Prospective, Observational, Multi-Center, Real-World Study of Toripalimab Injection in First-Line Treatment of Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Voluntarily participate and sign the informed consent form.\n* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC);\n* Scheduled to receive Toripalimab as first-line treatment;\n* Availability of traceable medical history records during the treatment period.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Known allergic to recombinant humanized anti-PD-1 monoclonal antibody drugs or their components；\n* Any other condition deemed by the investigator as unsuitable for inclusion in the study.",{"count":87,"type":21},1200,"OBSERVATIONAL","This is a prospective, observational, multi-center, real-world study evaluating the effectiveness and safety of Toripalimab (a PD-1 inhibitor) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The primary objective is to assess real-world progression-free survival (rwPFS). Secondary objectives include evaluating real-world objective response rate (rwORR), disease control rate (rwDCR), overall survival (rwOS), and safety. Approximately 1200 patients from multiple centers in China will be enrolled and followed according to routine clinical practice. Data will be collected from medical records and follow-up visits.",[91,31],"SCLC, Extensive Stage",[93,31,94],"Extensive stage SCLC","Real-World Study","2025-12-15",{"date":97,"type":42},"2025-12-29",{"date":99,"type":21},"2026-02",{"date":101,"type":21},"2028-08",{"name":103,"class":49},"Fudan University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":78},"100599590","phase-2-surufatinib-in-combination-with-neoadjuvant-chemo-immunotherapy-and-concurrent-chemoradiotherapy-for-patients-with-unresectable-locally-advanced-esophageal-squamous-cell-carcinoma-100599590","NCT07086469","Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","A Prospective, Single-arm, Phase II Clinical Trial of Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC).\n* Locally advanced, unresectable esophageal cancer assessed by endoscopic ultrasound and imaging studies, including esophagography, contrast-enhanced CT scans of the lower neck, chest, and upper abdomen, MRI of the lower neck and chest, whole-body bone scintigraphy, or PET\u002FCT; staged as T2-4, N0-3, M0-1 (M1 limited to supraclavicular lymph node metastasis).\n* Male or female patients aged 18 to 80 years.\n* No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy.\n* Expected life expectancy of at least 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ and bone marrow function defined as: Forced expiratory volume in one second (FEV1) ≥ 1000 mL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Creatinine clearance ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Total bilirubin ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.\n* Signed and dated informed consent form must be obtained prior to any study-related procedures.\n\nExclusion Criteria:\n\n* Participation in another clinical trial simultaneously, except for observational (non-interventional) studies.\n* Prior use of any targeted therapy.\n* Major surgery within 4 weeks prior to study entry (excluding vascular access procedures).\n* Uncontrolled comorbidities, including but not limited to active or ongoing infections, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, arrhythmias, active peptic ulcer disease or gastritis, intestinal perforation, bowel obstruction, active bleeding disorders, or psychiatric\u002Fsocial conditions that may impair compliance with study requirements or the ability to provide informed consent.\n* Performance status (PS) score of 2-4.\n* Presence of any of the following organ or bone marrow dysfunctions: Forced expiratory volume in one second (FEV1) \\\u003C 1000 mL; Absolute neutrophil count (ANC) \\\u003C 1.5 × 10⁹\u002FL; Platelet count \\\u003C 100 × 10⁹\u002FL; Hemoglobin \\\u003C 90 g\u002FL; Creatinine clearance \\\u003C 50 mL\u002Fmin calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976); Total bilirubin \\> 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2.5 × ULN.\n* Any condition that may interfere with the assessment of efficacy or safety of surufatinib.","80 Years",{"count":113,"type":21},69,[25],"The combination of surufatinib with neoadjuvant chemo-immunotherapy and definitive concurrent chemoradiotherapy represents a promising new therapeutic strategy that may further improve the prognosis of patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC). Therefore, we propose to conduct a prospective, single-arm, phase II clinical trial to evaluate the efficacy and safety of this regimen in patients with unresectable, locally advanced ESCC.",[31,62,117,63,118],"Neoadjuvant Immunochemotherapy","Esophageal Squamous Cell Carcinoma",[31,62,117,63,118],"2025-11-13",{"date":122,"type":42},"2025-11-17",{"date":124,"type":42},"2025-07-20",{"date":126,"type":21},"2029-07-19",{"name":77,"class":49},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":78},"100383864","phase-2-anlotinib-plus-toripalimab-as-first-line-treatment-for-advanced-gastric-cancer-with-ecog-2-apical-gc-100383864","NCT04278222","Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)","Efficacy and Safety of Anlotinib Plus Toripalimab as First-line Regimen in Frail Patients (ECOG 2) With Advanced Gastric Cancer (APICAL-GC): an Open-label, Single Arm, Phase II Trial","Inclusion Criteria:\n\n* Histologically confirmed, UICC stage IV gastric cancer;\n* no prior systematic anti-cancer treatment and relapse or metastases was occurred more than 12 months after adjuvant chemotherapy;\n* at least one measurable lesion;\n* received radiotherapy 3 weeks before recruitment, but the lesion undergoing radiotherapy could not be used to calculate clinical benefit using RECISET criteria;\n* ECOG performance status 2;\n* the main organ function to meet the following criteria: HB ≥ 90g \u002F L, ANC ≥ 1.5 × 109 \u002F L, PLT ≥ 80 × 109 \u002F L,BIL \\\u003C1.5 times the upper limit of normal (ULN), ALT and AST \\\u003C2.5 × ULN and if liver metastases, BIL \\\u003C 3 × ULN, ALT and AST \\\u003C5 × ULN; Serum Cr ≤ 1.5 × ULN;\n* Patient's written declaration of consent obtained;\n* Estimated life expectancy \\> 3 months;\n\nExclusion Criteria:\n\n* harboring HER2 positive including IHC 3+ or IHC 2+ with Fish positive;\n* dMMR\u002FMSI-H;\n* Myocardial infarction, unstable angina pectoris, Grade III or IV heart failure (NYHA classification);\n* have received anlotinib or other immune checkpoint inhibitor ;\n* with known or clinically suspected brain metastases, autoimmune disease, organ transplantation ;\n* severe wounds or surgery 4 weeks before recruitment;\n* received glucocorticoid (more than 10mg prednisone ) and immunosuppressive agents;\n* History of a second malignancy during the past 5 years before inclusion in the study or during participation in the study, with the exception of a dermal basal cell or squamous cell carcinoma or cervical carcinoma in situ, if these were treated curatively.\n* pregnancy or breast feeding;\n* absent or restricted legal capacity;\n* a significant concomitant disease which, in the investigating physician's opinion, rules out the patient's participation in the study",{"count":136,"type":21},24,[25],"This study is designed to evaluate the efficacy and safety of the combination of Anlotinib wiht Toripalimab in advanced gastric cancer with ECOG 2 as first-line regimen.",[140,141,142,31],"Gastric Cancer","Immunotherapy","Anlotinib","2024-07-09",{"date":145,"type":42},"2024-07-10",{"date":147,"type":42},"2020-02-10",{"date":149,"type":21},"2024-12-31",{"name":151,"class":49},"Shanghai Changzheng Hospital"]